Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Scotiabank initiated coverage of Vertex Pharmaceuticals (VRTX) with an Outperform rating and $495 price target Published first on TheFly – the ...
Scotiabank analyst Louise Chen initiated coverage of 10 large cap biopharma companies with an “out-of-consensus” positive sector view, citing a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback